- Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream
- According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective
- The company also released partial results from a human clinical study evaluating DehydraTECH-processed CBD for potential application against hypertension, which evidenced a rapid and sustained drop in blood pressure
- Growing hypertension and antiviral therapeutics market represent a potential win for Lexaria
In July, Lexaria Bioscience (NASDAQ: LEXX), a drug delivery technology developer, issued several key announcements that, in addition to highlighting the progress made in advancing its patented DehydraTECH(TM) drug delivery technology, form the basis of analysis in a recent Newsfile Corp. article (https://ibn.fm/1BOgg).
On July 22, the Kelowna-based global innovator reviewed its successful 2021 antiviral drug program. With diseases caused by viruses, including HIV/AIDS, influenza, and, more recently, COVID-19, having made the demand and need for effective antiviral drugs via oral delivery that are available to all more profound than ever before, Lexaria has made strides. The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish. Still, it continues to evaluate the data generated from the program (https://ibn.fm/MQIDe).
According to the Newsfile article, the antivirals represent a much broader market for DehydraTECH, especially currently, because in response to COVID-19, they “are having a moment.” Even so, “the same technology can be applied to rendering treatments for AIDS and other infectious diseases more effective. Antihistamines and anti-inflammatory drugs, as well as such therapeutics as remdesivir, have all been shown to be enhanced by DehydraTECH in animal studies,” the article notes.
Lexaria is likely to benefit from the projected growth in the global antiviral therapeutics market, which is expected to surge to $67.76 billion in 2026 from $51.26 billion in 2020, representing a 4.76% CAGR. Analysts at Mordor Intelligence peg this growth on robust R&D investment in antiviral drugs by public and private companies (https://ibn.fm/NbkIA).
Notably, the antiviral program is just one of several others Lexaria is focusing on at present. Another applied R&D program, which also featured prominently in the Newsfile article, is hypertension. On July 29, the company released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension (https://nnw.fm/9WvGd). (https://cnw.fm/rYTu4). (https://ibn.fm/fmGyE).
The study revealed a rapid and sustained drop in blood pressure with DehydraTECH-processed CBD and was most pronounced within the first 10 to 50 minutes of the study. This evidence reinforced the company’s pre-existing findings and further demonstrated that its drug delivery technology offers superior performance over generic CBD controls (https://ibn.fm/eYP1p).
“That CBD would be among the first use cases for such a platform as DehydraTECH makes sense,” reads the Newsfile article, “FDA-approved for pediatric seizure purposes since 2018, it has gained a great deal of traction over a short period of time. While its most closely identified delivery vector is hemp cigarettes, these can damage lungs as much as pills can damage livers.”
The article further notes that hypertension represents a new market for CBD and a potential huge win for Lexaria. Valued at $27.8 billion in 2018, the antihypertensive drug market is expected to grow at a CAGR of about 2% from 2019 to 2027 (https://ibn.fm/eMoJz).
On July 28, Lexaria announced that DehydraTECH is available for sale in more than 7,000 stores across the US, in what CEO Chris Bunka noted was an indication that the delivery technology is enabling increased market share and sales growth for its expanding list of corporate clients (https://ibn.fm/U4ws7).
The article also highlights Lexaria’s financial information. “Its balance sheet is clean, but that is in large part due to Lexaria’s ability to raise money on financial markets. Earnings are not what one would hope for, and yet the market cap is roughly 10x assets, suggesting high confidence in management,” it concludes.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
